AMRI and Proteros Biostructures form strategic alliance
Integrated solutions from one point of service and contact
AMRI and Proteros Biostructures have signed an agreement for a joint offering to the life sciences industry. Proteros, an expert in the field of protein crystallisation and X-ray structural analysis, provides services that complement AMRI’s existing drug discovery capabilities in chemistry, in vitro biology, drug metabolism and pharmacokinetics services.
Proteros’ expertise in structural biology services combined with AMRI’s expansive discovery and development capabilities provides biotechnology and pharmaceutical companies throughout the world access to a portfolio of contract services from two companies known for their high level of expertise, dedication to quality and track record of success.
‘We are excited about this new relationship that expands the depth and level of service we can offer to customers around the globe looking for integrated solutions from one point of service and contact,’ said Dr Thomas E. D’Ambra, AMRI chairman, president and ceo.
